
TWiV 724: COVID-19 clinical update #51 with Dr. Daniel Griffin
About this episode
In COVID-19 clinical update #51, Daniel Griffin reviews use of two masks, effectiveness of testing in nursing homes, updates on vaccines, use of nonsteroidal anti-inflammatory drugs, little effect of vitamin D and remdesivir in clinical studies, and a long COVID research initiative from NIH.
Hosts: Daniel Griffin and Vincent Racaniello
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Updated NYC mask guidance (NYC Health)
- Two masks recommended (CDC)
- Effectiveness of testing in nursing homes (Clin Inf Dis)
- Vaccine reactogenicity and antibody response after COVID-19 (medRxiv)
- Bamlanivimab alone or with Etesevimab (JAMA)
- Non-steroidal anti-inflammatory drugs and death (BMJ)
- Budesonide and COVID-19 (medRxiv)
- No effect of vitamin D high dose (JAMA)
- Remdesivir little effect on hospitalized patients (NEJM)
- Sequelae 6 months after infection (JAMA)
- Long COVID initiative (NIH)
- Letters read on TWiV 724
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
Get every episode summarized
Each time This Week in Virology publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from This Week in Virology

TWiV 1309: Maybe they're all cancer vaccines
This Week in Virology

TWiV 1308: Clinical update with Dr. Daniel Griffin
This Week in Virology

TWiV 1307: My heart breaks for flu
This Week in Virology

TWiV 1306: Clinical update with Dr. Daniel Griffin
This Week in Virology